Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer – Narrowing the Gap Between Bench and Bedside

Angiogenesis in metastatic castration-resistant prostate cancer (mCRPC) has been extensively investigated as a promising druggable biological process. Nonetheless, targeting angiogenesis has failed to impact overall survival (OS) in patients with mCRPC despite promising preclinical and early clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Solimando, Antonio Giovanni, Kalogirou, Charis, Krebs, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866833/
https://www.ncbi.nlm.nih.gov/pubmed/35222436
http://dx.doi.org/10.3389/fimmu.2022.842038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866833/
https://www.ncbi.nlm.nih.gov/pubmed/35222436
http://dx.doi.org/10.3389/fimmu.2022.842038

Ejemplares similares